Back to top
more

Jazz Pharmaceuticals (JAZZ)

(Delayed Data from NSDQ)

$109.67 USD

109.67
376,838

+0.11 (0.10%)

Updated Apr 23, 2024 04:00 PM ET

After-Market: $109.74 +0.07 (0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Alkermes' (ALKS) ALKS 2680 Betters Wakefulness in Phase Ib Study

by Zacks Equity Research

Alkermes (ALKS) reports positive top-line data from a phase Ib, proof-of-concept study investigating ALKS 2680 for the treatment of narcolepsy.

Kinjel Shah headshot

Pharma Stock Roundup: AZN Voydeya Gets FDA Nod, MRK KRAS Inhibitor Enters Phase III

by Kinjel Shah

FDA approves AstraZeneca's (AZN) Voydeya (danicopan) in the United States as add on therapy to its other C5 inhibitors. Merck (MRK) begins a phase III study on its oral KRAS G12C inhibitor candidate.

Merck (MRK) Begins Phase III NSCLC Study on KRAS Candidate

by Zacks Equity Research

Merck's (MRK) phase III study will evaluate KRAS G12C inhibitor candidate MK-1084 for first-line treatment of certain patients with metastatic NSCLC.

Axsome (AXSM) Begins Solriamfetol Binge Eating Phase III Study

by Zacks Equity Research

Axsome's (AXSM) phase III ENGAGE study is set to evaluate the efficacy and safety of solriamfetol for the treatment of binge eating disorder in adults.

Why Is Jazz (JAZZ) Up 1.3% Since Last Earnings Report?

by Zacks Equity Research

Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Axsome's (AXSM) Narcolepsy Drug Study Meets Primary Goal

by Zacks Equity Research

Data from a late-stage study shows that a five-week treatment with Axsome's (AXSM) experimental narcolepsy drug reduced weekly cataplexy attacks by 83%, compared to 66% for placebo.

Axsome (AXSM) Begins Dosing in Depression Study on Sunosi

by Zacks Equity Research

Axsome (AXSM) doses the first patient in the phase III PARADIGM study evaluating Sunosi (solriamfetol) for treating major depressive disorder. The stock rises 6%.

Jazz (JAZZ) Q3 Earnings Lag, Revenues in Line With Estimates

by Zacks Equity Research

Jazz's (JAZZ) fourth-quarter earnings miss estimates while sales meet the mark. Shares drop 1.5% post the announcement.

Here's What Key Metrics Tell Us About Jazz (JAZZ) Q4 Earnings

by Zacks Equity Research

The headline numbers for Jazz (JAZZ) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Jazz Pharmaceuticals (JAZZ) Q4 Earnings Lag Estimates

by Zacks Equity Research

Jazz (JAZZ) delivered earnings and revenue surprises of -4.56% and 0.37%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Exploring Analyst Estimates for Jazz (JAZZ) Q4 Earnings, Beyond Revenue and EPS

by Zacks Equity Research

Besides Wall Street's top -and-bottom-line estimates for Jazz (JAZZ), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2023.

Ardelyx (ARDX) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Ardelyx (ARDX) delivered earnings and revenue surprises of -33.33% and 0.18%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Axsome (AXSM) Stock Falls Despite Q4 Earnings & Revenue Beat

by Zacks Equity Research

Axsome (AXSM) stock declines despite narrower-than-expected loss in the fourth quarter of 2023. Its sales also beat estimates.

JAZZ Boosts Oncology Pipeline With KRAS Inhibitor Program

by Zacks Equity Research

JAZZ inks a deal to acquire global rights to Redx Pharma's KRAS inhibitor program to strengthen its early-stage oncology pipeline.

Axsome (AXSM) Stock Rises on Stellar Q4 Preliminary Results

by Zacks Equity Research

Axsome (AXSM) issues encouraging preliminary results for the fourth quarter and full-year 2023. The company also provides regulatory updates on its pipeline candidates. Shares rise.

Jazz Pharmaceuticals' (JAZZ) PTSD Drug Misses Study Goals

by Zacks Equity Research

After a mid-stage study fails to show any improvement in its primary or secondary endpoints, Jazz (JAZZ) plans to scrap the development of its PTSD drug.

Why Is Jazz (JAZZ) Up 2.6% Since Last Earnings Report?

by Zacks Equity Research

Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Market Edge Highlights: Canopy Growth, Tilray Brands, Constellation Brands, Innovative Industrial Properties and Jazz Pharmaceuticals

by Zacks Equity Research

Canopy Growth, Tilray Brands, Constellation Brands, Innovative Industrial Properties and Jazz Pharmaceuticals are part of the Zacks Market Edge blog.

Tracey Ryniec headshot

Pot Stocks: Values or Traps?

by Tracey Ryniec

Pot stocks used to be hot but many have plunged over the last 2 years. Are there deals?

Ligand (LGND) Beats on Q3 Earnings & Sales, Raises '23 View

by Zacks Equity Research

Ligand Pharmaceuticals (LGND) reports encouraging third-quarter results as earnings and sales beat estimates. Management raises the 2023 financial outlook.

Jazz (JAZZ) Lags Q3 Earnings, Beats Sales, Raises '23 View

by Zacks Equity Research

Jazz (JAZZ) reports mixed results in third-quarter 2023. However, shares rose 2.5% post the announcement, likely on the back of raised guidance for 2023.

Compared to Estimates, Jazz (JAZZ) Q3 Earnings: A Look at Key Metrics

by Zacks Equity Research

Although the revenue and EPS for Jazz (JAZZ) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Unlocking Q3 Potential of Jazz (JAZZ): Exploring Wall Street Estimates for Key Metrics

by Zacks Equity Research

Besides Wall Street's top -and-bottom-line estimates for Jazz (JAZZ), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2023.

Axsome (AXSM) Q3 Loss Widens, Revenues Surpass Estimates

by Zacks Equity Research

Axsome (AXSM) incurs a wider-than-expected loss in the third quarter of 2023 while sales beat estimates. The company's shares declined post earnings announcement.

Sage Therapeutics, Inc. (SAGE) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Sage Therapeutics, Inc. (SAGE) delivered earnings and revenue surprises of -6.44% and 69.89%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?